SCHEMBL1879310

SCHEMBL1879310

CC(=O)c1cccc(CCl)c1O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRA1 P14867 2/20 0.43
GABRB2 P47870 2/20 0.43
HMGB1 P09429 1/20 0.43
IAPP P10997 2/20 0.41
ALDH1A1 P00352 3/20 0.38
LMNA P02545 2/20 0.38
HTT P42858 1/20 0.38
KDM4E B2RXH2 3/20 0.38
MAPT P10636 2/20 0.38
MEN1 O00255 1/20 0.38
NSD2 O96028 1/20 0.38
POLB P06746 1/20 0.38
KMT2A Q03164 1/20 0.38
MCL1 Q07820 1/20 0.38
THRB P10828 1/20 0.38
HPGD P15428 1/20 0.37
HSD17B10 Q99714 1/20 0.37
SMN1; SMN2 Q16637 2/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8117424 0.84 GABRA1 (0.64) GABRA1GABRB2HMGB1IAPPALDH1A1
SCHEMBL3291708 0.82 HMGB1 (0.62) HMGB1ALDH1A1LMNAKDM4EMEN1
SCHEMBL11347621 0.82 GABRA1 (0.45) GABRA1GABRB2HMGB1IAPPALDH1A1
SCHEMBL6445870 0.82 LMNA (0.43) ALDH1A1LMNAHTTKDM4EMAPT
SCHEMBL1367671 0.81 ALDH1A1 (0.39) GABRA1GABRB2HMGB1IAPPALDH1A1
SCHEMBL9263627 0.80 SMN1; SMN2 (0.40) GABRA1GABRB2HMGB1IAPPALDH1A1
SCHEMBL8124725 0.79 PRKCI (0.54) GABRA1GABRB2HMGB1IAPPALOX5
SCHEMBL28035846 0.79 AKR1B1 (0.52) GABRA1GABRB2HMGB1IAPPALDH1A1
SCHEMBL31346667 0.79 AKR1B1 (0.52) GABRA1GABRB2HMGB1IAPPALDH1A1
SCHEMBL26162757 0.79 GABRA1 (0.42) GABRA1GABRB2ALDH1A1LMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117820200-A Heterobivalent compound taking piperidinoindenone-salicylic acid as parent, and preparation method and application thereof 合肥工业大学 2024-04-05 CN claimed
CN-120117987-A Arylalkanoic acid phloroglucinol ester compound, preparation method and application thereof 南华大学 2025-06-10 CN disclosed
CN-118978524-A Nitrazonit derivative and medical application thereof 绍兴君科臻元医药科技有限公司 2024-11-19 CN disclosed
CN-112480104-B Nitrazonit derivative and medical application thereof 绍兴君科臻元医药科技有限公司 2024-06-18 CN disclosed
CN-117820200-A Heterobivalent compound taking piperidinoindenone-salicylic acid as parent, and preparation method and application thereof 合肥工业大学 2024-04-05 CN disclosed
CN-115154401-B Anti-inflammatory and soothing emulsion and preparation method thereof 武汉诺安药业有限公司 2023-10-10 CN disclosed
US-20210353579-A1 HIGH PENETRATION COMPOSITIONS AND USES THEREOF TECHFIELDS PHARMA CO LTD (CN) 2021-11-18 US disclosed
EP-3279182-B1 ACETYLSALICYLIC ACID DERIVATIVE CRYSTAL AND PREPARATION METHOD AND USE THEREOF ZHEJIANG YUEJIA PHARMACEUTICALS CO LTD (CN) 2021-05-26 EP disclosed
US-10882817-B2 Acetylsalicylic acid derivative crystal, its preparation method and use ZHEJIANG YUEJIA PHARMACEUTICALS CO., LTD (CN) 2021-01-05 US disclosed
CN-109422788-B Preparation method of cytarabine hydrochloride 北京斯利安药业有限公司 2020-11-20 CN disclosed
EP-0483881-B1 3-Amidoindolyl derivatives MERRELL PHARMA INC (US) 1998-01-21 EP disclosed
US-5686469-A ANTIINFLAMMATORY AGENTS MILES INC. (US) 1997-11-11 US disclosed
US-5506224-A ADMINISTERING TO TREAT MAMMALIAN PATHOLOGIES INVOLVING MAST CELL DEGRANULATION AS CONSEQUENCE OF NEUROGENIC AND/OR IMMUNOGENIC HYPERSTIMULATION LIFEGROUP S.P.A. (IT) 1996-04-09 US disclosed
EP-0513285-B1 IMIDAZOL-2-YL DERIVATIVES OF SUBSTITUTED BICYCLIC COMPOUNDS AND PROCESS FOR THEIR PREPARATION PHARMACIA SPA (IT) 1996-01-24 EP disclosed
US-5356920-A Anticholesterol, antilipemic agent FARMITALIA CARLO ERBA SRL. (IT) 1994-10-18 US disclosed
EP-0610745-A2 Novel aminomethylene derivatives as immunosuppressants Bayer Corporation (US) 1994-08-17 EP disclosed
WO-1992009582-A1 IMIDAZOL-2-YL DERIVATIVES OF SUBSTITUTED BICYCLIC COMPOUNDS AND PROCESS FOR THEIR PREPARATION FARMITALIA CARLO ERBA SRL (IT) 1992-06-11 WO disclosed
US-4985440-A Hypolipidaemic imidazol-2-yl-derivatives of bicyclic compounds FARMITALIA CARLO ERBA, S.R.L. (IT) 1991-01-15 US disclosed
EP-0375746-A1 HYPOLIPIDAEMIC IMIDAZOL-2-YL-DERIVATIVES OF BICYCLIC COMPOUNDS AND PROCESS FOR THEIR PREPARATION FARMITALIA CARLO ERBA S.r.l. (IT) 1990-07-04 EP disclosed
WO-1989008646-A1 HYPOLIPIDAEMIC IMIDAZOL-2-YL-DERIVATIVES OF BICYCLIC COMPOUNDS AND PROCESS FOR THEIR PREPARATION FARMITALIA CARLO ERBA S.R.L. (IT) 1989-09-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10882817-B2 Acetylsalicylic acid derivative crystal, its preparation method and use ACMSD, SSB, NFKBIA GABRA1 1454/4885GABRB2 2132/4885HMGB1 1323/4885
US-20210353579-A1 HIGH PENETRATION COMPOSITIONS AND USES THEREOF HPGDS, PTGIS, PTGES GABRA1 3682/4885GABRB2 4131/4885HMGB1 53/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.